Clinical trial
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
NCT00003184 · Providence Cancer Center, Earle A. Chiles Research Institute, Other · Completed
Key facts
| NCT number | NCT00003184 |
|---|---|
| Title | Vaccine Therapy in Treating Women With Metastatic Breast Cancer |
| Official title | Phase I Trial Using a CD80-Modified Allogeneic Breast Cancer Cell Line to Vaccinate HLA-A2-Positive Women With Breast Cancer |
| Lead sponsor | Providence Cancer Center, Earle A. Chiles Research Institute, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | BCG vaccine, CD80 breast cancer vaccine, sargramostim |
| Start date | Aug 1, 1996 |
| Completion | Jul 1, 2003 |
| First posted | Jul 11, 2003 |
| Last update posted | Apr 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: